MRD-directed and risk-adapted individualized stratified treatment of AML

查看全文 作　　者：Yijing [1]Zhao;Hanfei [2,3]Guo;Yingjun [1]Chang

机构地区：[1]Peking University People’s Hospital,Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,China;[2]Stanford University Medical School,VA Palo Alto Health Care System,Palo Alto 94304,USA;[3]the First Hospital of Jilin University,Cancer Center,Changchun 133021,China

出　　处：《Chinese Journal of Cancer Research》索引2023年第35卷第5期,共19页

基　　金：supported by Beijing Nova Program of Science and Technology (No.Z211100002121058);National Natural Science Foundation of China (No.82100168);Peking University People’s Hospital Research and Development Funds (No.RS2020-03,RDY2020-29);Peking University Medicine Fund of Fostering Young Scholars’ Scientific & Technological Innovation;“the Fundamental Research Funds for the Central Universities”(No.BMU2021PYB005) 摘　　要：Measurable residual disease(MRD)has been widely recognized as a biomarker for deeply evaluating complete remission(CR),predicting relapse,guiding pre-emptive interventions,and serving as an endpoint surrogate for drug testing.However,despite the emergence of new technologies,there remains a lack of comprehensive understanding regarding the proper techniques,sample materials,and optimal time points for MRD assessment.In this review,we summarized the MRD methods,sample sources,and evaluation frequency according to the risk category of the European Leukemia Net(ELN)2022.Additionally,we emphasize the importance of properly utilizing and combining these technologies.We have also refined the flowchart outlining each time point for preemptive interventions and intervention paths.The evaluation of MRD in acute myeloid leukemia(AML)is sophisticated,clinically applicable,and technology-dependent,and necessitates standardized approaches and further research. 关键词：Measurable residual disease acute myeloid leukemia risk stratification

相关文献

参考文献（136）
引证文献（1）
耦合文献（0）

参考文献(136)

引证文献(1)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

MRD-directed and risk-adapted individualized stratified treatment of AML

参考文献(136)

引证文献(1)

用户提示